DGLA-Induced Ferroptosis in Acute Myeloid Leukemia: Lipid Metabolism and ACSL4 as Therapeutic Targets

Study Background and Research Question

Acute myeloid leukemia (AML) is a clinically challenging hematologic malignancy characterized by high relapse rates and frequent chemoresistance. Traditional chemotherapeutic strategies predominantly induce apoptosis in AML cells, but the emergence of apoptosis resistance remains a significant barrier to effective treatment. Recent interest has shifted toward alternative cell death modalities, such as ferroptosis—a regulated, iron-dependent form of cell death driven by lipid peroxidation—as a possible strategy to circumvent apoptosis resistance. However, the mechanistic link between lipid metabolism and ferroptosis in AML remains insufficiently understood. The study by Jiang et al. (Translational Oncology, 2025) specifically investigates whether manipulating lipid metabolism via exogenous fatty acids can trigger ferroptosis in AML cells, and which molecular pathways are responsible.

Key Innovation from the Reference Study

The central innovation of this work is the identification of exogenous dihomo-γ-linolenic acid (DGLA) as a potent ferroptosis inducer in AML cells. The study elucidates that DGLA’s effect is critically dependent on acyl-CoA synthetase long-chain family member 4 (ACSL4), an enzyme involved in polyunsaturated fatty acid metabolism. By linking ACSL4-mediated lipid metabolic reprogramming to ferroptosis sensitivity, the study provides a mechanistic framework for exploiting lipid metabolism in the design of novel anti-leukemic therapies.

Methods and Experimental Design Insights

The authors employed a multi-pronged approach combining high-throughput targeted metabolomics, gene knockout models, and in vitro and in vivo assays:

• Metabolomics Screening: AML cell lines were analyzed post-DGLA treatment to identify fatty acids and lipid metabolites associated with ferroptosis sensitivity.
• Functional Validation: Exogenous supplementation with DGLA and other candidate fatty acids was conducted to assess their ability to induce ferroptosis, as measured by lipid peroxidation and cell viability assays.
• Genetic Manipulation: ACSL4 knockout AML cells were generated to directly test the requirement of this enzyme for DGLA-induced ferroptosis. Rescue experiments confirmed the specificity of the effect.
• In Vivo Models: Mice bearing AML xenografts received DGLA-enriched diets, allowing evaluation of ferroptosis induction and leukemia progression in a physiological context.

These methods collectively enabled a rigorous dissection of the metabolic pathways underpinning ferroptosis in AML.

Core Findings and Why They Matter

The study’s primary findings are as follows:

• Lipidomic Shifts in Ferroptosis: Twelve fatty acids, including DGLA, arachidonic acid, and docosahexaenoic acid, were significantly altered during ferroptosis in AML cells (Jiang et al., 2025).
• DGLA as a Ferroptosis Trigger: Exogenous DGLA alone was sufficient to induce ferroptosis in AML cells, evidenced by increased lipid peroxidation and reactive oxygen species accumulation.
• ACSL4 Dependency: Genetic knockout of ACSL4 abrogated the ferroptotic effects of DGLA, highlighting ACSL4 as a molecular gatekeeper of DGLA-induced lipid metabolic reprogramming and cell death.
• Therapeutic Relevance: Dietary DGLA restricted AML growth and induced ferroptosis in murine xenograft models, demonstrating translational potential.

These results position ACSL4-driven metabolic reprogramming as a vulnerability in AML that can be exploited to induce cell death even when apoptosis is compromised. This insight may inform future therapeutic strategies aimed at overcoming drug resistance.

Comparison with Existing Internal Articles

This study’s focus on ferroptosis expands the landscape of programmed cell death research, which has traditionally emphasized apoptosis and, more recently, pyroptosis. Internal resources such as "HOXC8 Suppresses Pyroptosis in NSCLC via Caspase-1 Regulation" and several comprehensive reviews of Z-YVAD-FMK as a caspase-1 inhibitor, describe how manipulating the inflammasome-caspase-1 axis can modulate pyroptotic and apoptotic cell death in cancer models.

While caspase-1 inhibitors like Z-YVAD-FMK (see Unraveling Caspase-1 Inhibition in Tumorigenesis) are indispensable for dissecting apoptosis and pyroptosis pathways, the present reference study highlights a distinct, caspase-independent pathway—ferroptosis—where cell death is executed via lipid peroxidation rather than protease cascades. Together, these bodies of work illustrate the expanding toolkit for programmed cell death research in oncology, underscoring the need for precise molecular tools whether targeting the caspase cascade or lipid metabolism.

Limitations and Transferability

There are several caveats and open questions:

• Cell Line Specificity: The findings are based on established AML cell lines and specific xenograft models; primary human leukemic cells or diverse genetic backgrounds may respond differently.
• Dietary Translation: While DGLA-enriched diets suppressed leukemia in mice, the pharmacokinetics, tolerability, and efficacy in humans remain to be established.
• Pathway Complexity: The study focuses on ACSL4-dependent ferroptosis, but cross-talk with other metabolic and cell death pathways (e.g., apoptosis, pyroptosis) requires further investigation, especially in the context of combination therapies.
• Therapeutic Maturity: DGLA and ACSL4-targeted approaches are at a preclinical stage; clinical translation will require careful evaluation of specificity, toxicity, and resistance mechanisms.

Despite these limitations, the mechanistic clarity and translational rationale provided by this study support further preclinical development of ferroptosis-based AML therapies.

Protocol Parameters

• DGLA supplementation: DGLA concentration and exposure times should be optimized based on cell line sensitivity; the reference study used exogenous doses to trigger ferroptosis in AML cells in vitro and supplemented rodent diets in vivo.
• ACSL4 knockout validation: Employ CRISPR/Cas9 or shRNA to confirm the dependency of DGLA-induced ferroptosis on ACSL4 activity.
• Lipid peroxidation assay: Quantify malondialdehyde (MDA) or 4-hydroxynonenal (4-HNE) as markers of lipid peroxidation during ferroptosis induction.
• Apoptosis and pyroptosis controls: Parallel measurement of caspase activity (e.g., with caspase-1 inhibitors like Z-YVAD-FMK) may help distinguish between overlapping cell death pathways, as detailed in related protocol articles.

Research Support Resources

For researchers seeking to further dissect the interplay between ferroptosis, apoptosis, and pyroptosis, precise molecular tools are essential. Z-YVAD-FMK (SKU A8955) from APExBIO is a widely used, irreversible caspase-1 inhibitor suitable for apoptosis and pyroptosis research workflows, including differentiation between cell death modalities in cancer studies. Its selectivity and protocol compatibility make it a valuable addition when mapping cell death pathways alongside ferroptosis research.